506 filings
Page 3 of 26
10-K
2022 FY
NERV
Minerva Neurosciences Inc
Annual report
8 Mar 23
6:30am
SC 13G/A
NERV
Minerva Neurosciences Inc
14 Feb 23
Minerva Neurosciences / Point72 Asset Management ownership change
12:00am
SC 13G/A
Vanguard Group Inc
9 Feb 23
Minerva Neurosciences / VANGUARD ownership change
11:27am
SC 13G/A
NERV
Minerva Neurosciences Inc
1 Feb 23
Minerva Neurosciences / FEDERATED HERMES ownership change
11:16am
8-K
NERV
Minerva Neurosciences Inc
28 Dec 22
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
8:24am
8-K
NERV
Minerva Neurosciences Inc
16 Dec 22
Departure of Directors or Certain Officers
4:31pm
4
Remy Luthringer
14 Dec 22
Minerva Neurosciences / Remy Luthringer ownership change
4:50pm
4
Geoff Race
14 Dec 22
Minerva Neurosciences / Geoff Race ownership change
4:48pm
4
NERV
Minerva Neurosciences Inc
14 Dec 22
Minerva Neurosciences / Frederick W Ahlholm ownership change
4:47pm
8-K
NERV
Minerva Neurosciences Inc
2 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:02pm
10-Q
2022 Q3
NERV
Minerva Neurosciences Inc
Quarterly report
9 Nov 22
7:00am
8-K
NERV
Minerva Neurosciences Inc
17 Oct 22
Other Events
8:37am
EFFECT
NERV
Minerva Neurosciences Inc
26 Sep 22
Notice of effectiveness
12:15am
UPLOAD
NERV
Minerva Neurosciences Inc
21 Sep 22
Letter from SEC
12:00am
UPLOAD
NERV
Minerva Neurosciences Inc
21 Sep 22
Letter from SEC
12:00am
CORRESP
NERV
Minerva Neurosciences Inc
21 Sep 22
Correspondence with SEC
12:00am
S-3
NERV
Minerva Neurosciences Inc
Shelf registration
14 Sep 22
5:22pm
CORRESP
NERV
Minerva Neurosciences Inc
14 Sep 22
Correspondence with SEC
12:00am
UPLOAD
NERV
Minerva Neurosciences Inc
12 Sep 22
Letter from SEC
12:00am
8-K
NERV
Minerva Neurosciences Inc
9 Sep 22
Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market
4:30pm